All Access Fund
All Access Fund 2024

AlphaRose Therapeutics

About AlphaRose Therapeutics

AlphaRose makes genetic medicines affordable and accessible for millions of patients that are unaddressed by pharma. Using their all in one platform, AlphaRose plans to make hundreds of treatments for less time and money than pharma spends to make one. The company is co-founded by executives from the most successful rare disease company to date, Genzyme Corporation, and collectively the team has commercialized over 20 rare disease products globally. The companies' lead product, "Rosiphersen," is slated for clinical trials in early 2026. For the first time in history, families no longer have to rely on the pharmaceutical industry to decide whether their loved ones receive treatment.


  • Artificial Intelligence